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ABSTRACT 
In oncology trials, control group patients often switch onto the experimental treatment during follow-up, usually 
after disease progression. In this case, an intention-to-treat analysis will not address the policy question of 
interest ± that of whether the new treatment represents an effective and cost-effective use of health care 
resources, compared to the standard treatment. Rank preserving structural failure time models (RPSFTM), 
inverse probability of censoring weights (IPCW) and two-stage estimation (TSE) have often been used to adjust 
for switching to inform treatment reimbursement policy decisions. TSE has been applied using a simple 
approach (TSEsimp), assuming no time-dependent confounding between the time of disease progression and the 
time of switch. This is problematic if there is a delay between progression and switch. In this paper we introduce 
TSEgest, which uses structural nested models and g-estimation to account for time-dependent confounding, and 
compare it to TSEsimp, RPSFTM and IPCW. We simulated scenarios where control group patients could switch 
onto the experimental treatment with and without time-dependent confounding being present. We varied 
switching proportions, treatment effects and censoring proportions. We assessed adjustment methods according 
to their estimation of control group restricted mean survival times that would have been observed in the absence 
of switching. All methods performed well in scenarios with no time-dependent confounding. TSEgest and 
RPSFTM continued to perform well in scenarios with time-dependent confounding, but TSEsimp resulted in 
substantial bias. IPCW also performed well in scenarios with time-dependent confounding, except when inverse 
probability weights were high in relation to the size of the group being subjected to weighting, which occurred 
when there was a combination of modest sample size and high switching proportions. TSEgest represents a 
useful addition to the collection of methods that may be used to adjust for treatment switching in trials in order 
to address policy-relevant questions.  
KEYWORDS 
Treatment switching; treatment crossover; survival analysis; overall survival; oncology; health technology 
assessment; time-to-event outcomes; prediction; time-dependent confounding; structural nested models; g-
estimation; counterfactual 
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INTRODUCTION 
In recent times there has been considerable interest in methods that allow treatment effects to be estimated 
adjusting for treatment changes that occur in randomised controlled trials (RCTs).[1-7] Treatment pathways 
observed in RCTs often do not reflect those that would be observed in reality, and therefore intention to treat 
(ITT) analyses may not address the question of interest. For instance, in clinical trials of new oncology 
therapies, patients who are randomised to the control group are often permitted to switch onto the experimental 
treatment during the trial, usually after disease progression. In such circumstances, the ITT analysis provides an 
estimate of the effect of immediate compared to deferred experimental treatment. An alternative estimand might 
consider the effectiveness of immediate experimental treatment compared to no experimental treatment. This is 
particularly important in health technology assessment (HTA), where the objective is usually to identify whether 
inserting a new treatment into the treatment pathway at the line of therapy designated by its licence represents 
an effective and cost-effective use of healthcare resources, compared to retaining the existing treatment 
pathway. In HTA treatment benefits are usually summarised using estimates of mean (quality adjusted) survival 
advantages.[8-11] 
Treatment changes are to be expected in any clinical trial. If these changes reflect what would happen in practice 
it is not necessary to make adjustments to enable appropriate HTA decision making. However, switching from 
the control group onto the experimental treatment does cause a problem. If the HTA decision maker does not 
recommend a new treatment it will not be available in the health system. The HTA decision problem involves a 
comparison of a world in which the new treatment exists (and is given at its licensed line of therapy) to a world 
in which the new treatment does not exist at all. Therefore, if patients randomised to the control group of an 
RCT are permitted to receive the experimental treatment at some point during the trial, the observed treatment 
pathway is not relevant for the HTA decision problem.  
This is illustrated in Figure 1. The horizontal axis represents survival time, consisting of progression-free 
survival (PFS) and post-progression survival (PPS). Rows 1 and 2 illustrate what we would ideally observe in an 
RCT. Row 1 (the upper row) illustrates survival in the control group in the absence of any switching onto the 
experimental treatment, and Row 2 (the middle row) illustrates survival in the experimental group. However, 
when control group patients are permitted to switch onto the experimental treatment at the point of disease 
progression, we observe Row 3 (the bottom row) and not Row 1. If switching occurs, an ITT analysis provides 
an estimate of the difference between Row 2 and Row 3. In contrast, the HTA decision maker is likely to require 
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an estimate of the difference between Row 2 and Row 1 ± comparing a world where the experimental treatment 
exists to one where it does not. Therefore, the ITT analysis does not address the HTA decision problem; an 
analysis that adjusts for treatment switching is needed such that Row 2 can be compared to an estimated Row 1.  
Research on methods for adjusting for treatment switching in an RCT context have focussed on rank preserving 
structural failure time models (RPSFTM), inverse probability of censoring weights (IPCW) and two-stage 
estimation (TSE).[1-7,12-14] These methods have been included in analyses used to make reimbursement 
decisions on new cancer drugs around the world.[5] When attempting to adjust analyses to account for treatment 
switches that occur over time, the key difficulty is time-dependent confounding.[15] If a variable influences the 
treatment switch decision, is prognostic for the outcome of interest (such as survival), and is itself affected by 
treatment, it is a time-dependent confounder for the effect of treatment on outcome. The RPSFTM and IPCW 
approaches originate in the causal inference literature and, provided their assumptions hold, are able to provide 
unbiased adjusted treatment effects in the presence of time-dependent confounding.[16-18] In contrast, the TSE 
method uses a simple estimation procedure and is only appropriate when switching occurs after a specific 
disease-related time-point, referred to as a ³VHFRQGDU\EDVHOLQH´VXFKDVGLVHDVHSURJUHVVLRQ>2] The first stage 
of the method requires the post-secondary-baseline treatment effect in switchers to be estimated, but the method 
does not adjust for any time-dependent confounding that may occur between the secondary baseline and the 
time of switch. This may be reasonable when switching occurs either at or very soon after the secondary 
baseline (as depicted in Figure 1), but if there is an appreciable gap between the secondary baseline and the time 
of switch (as depicted in Figure 2) the TSE method may become biased.     
To illustrate this, first consider a simple case where switching can only occur immediately upon disease 
progression. Consider an RCT investigating the effectiveness of an experimental adjuvant treatment for non-
metastatic cancer, in which switching from the control group onto the experimental treatment is permitted at the 
point of disease progression. The TSE method would estimate the effect of switching by comparing post-
progression survival in control group switchers and non-switchers, adjusting for differences between switchers 
and non-switchers at the point of disease progression. The directed acyclic graph (DAG) [19] presented in 
Figure 3 illustrates the post-progression period for control group patients in this example. Upon disease 
progression, the decision as to whether or not a patient switches treatment (denoted by ଵܵ in Figure 3) is 
dependent on prognostic characteristics measured either at or before the time of disease progression (labelled 
଴ܸin Figure 3). Let us assume that receiving treatment prolongs survival (Y) and affects the probability of 
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metastatic disease developing at a later time-point (ܯଶ in Figure 3). Note that in this example (and throughout 
this paper), we consider a case where disease progression is distinct from metastatic disease ± first, disease 
progression may occur (as measured, for example, by an increase in tumour size) and subsequently the disease 
may become metastatic. ଵܵ has a direct effect on Y, and also an indirect effect through ܯଶ. In this case, an 
analyst using the TSE method to estimate the effect of ଵܵ on Y can simply adjust for ଴ܸ. ܯଶ is not a confounder 
because it is not a cause of ଵܵ and therefore does not need to be adjusted for in the analysis. 
Next, consider a more complex case, where switching can occur either at the point of disease progression or at 
an additional time-point thereafter (ܵଶ). The DAG presented in Figure 4 illustrates the post-progression period 
for control group patients in this case. Upon disease progression the decision as to whether or not a patient 
switches treatment ( ଵܵሻ is again dependent on prognostic characteristics measured at or before the time of 
disease progression ( ଴ܸ). Again receiving treatment prolongs survival (Y) and affects the probability of 
metastatic disease developing at a later time-point (ܯଶ) but in this case developing metastatic disease affects the 
FOLQLFLDQ¶VGHFLVLRQDVWRZKHWKHURUQRWa patient should subsequently change treatments (ܵଶ). In this case, an 
analyst using the TSE method to estimate the effect of switching must decide whether to include the occurrence 
of metastatic disease (ܯଶ) as a time-varying covariate in their statistical model. If they do not, the estimate of 
the treatment effect will be biased because patients who switch treatment have a different prognosis to those 
who do not switch ± this is known as confounding by indication,[15] and in Figure 4 is illustrated by the open 
backdoor path from ܵଶ ՚  ܯଶ ՜ ܻ. However, including metastatic disease as a time-varying covariate will also 
result in biased estimates of the treatment effect because part of the treatment effect occurs through reducing the 
likelihood of metastatic disease (the causal path from ଵܵ ՜ ܯଶ ՜ ܻ would be blocked). In this example ܯଶis a 
time-dependent confounder. The TSE method would produce biased estimates of the treatment effect because 
simple regression adjustment cannot deal with time-dependent confounders.  
It is possible to apply the TSE method using a more sophisticated estimation procedure (g-estimation) in order 
to obtain unbiased estimates in the presence of time-dependent confounding. Previous research attempted to 
assess such a technique, but found that it did not work well in realistic simulated scenarios ± the method often 
failed to converge and frequently resulted in high levels of bias.[12] In this paper we re-visit this. We improved 
the statistical program used to apply the method (stgest, for use in Stata [20]) ± principally by improving the g-
estimation algorithm used ± and tested this in a simulation study including scenarios with and without time-
dependent confounding. Our aims were to develop and assess a version of the TSE method that is capable of 
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adjusting for time-dependent confounding and to compare this to alternative adjustment methods in a range of 
scenarios. We focus on the problem typically seen in HTA,[1-7, 21,22] whereby a subset of control group 
patients switch onto the experimental treatment after disease progression and we wish to estimate what survival 
would have been in the control group as a whole if this switching had not occurred.  
METHODS 
In this section we first describe the TSE method using simple estimation (denoted TSEsimp) and using g-
estimation (TSEgest). We also summarise RPSFTM and IPCW, because these represent relevant comparator 
methods that can control for time-dependent confounding. We then describe the design of our simulation study.  
Adjustment methods 
Box 1 summarises the key assumptions used by each of the adjustment methods, in our context. We assume that 
switching is not a problem in the experimental group (that is, we only address switches from the control group 
onto the experimental treatment, not switches in the opposite direction). Below we provide more detail on each 
adjustment method, organised by concept, assumptions and modelling approach. 
Two-stage Estimation ± simple approach 
TSEsimp ± concept  
As previously described, TSE is designed to adjust for switching that occurs after a specific disease-related 
time-SRLQWUHIHUUHGWRDVD³VHFRQGDU\EDVHOLQH´[12] The TSE method involves first estimating the effect 
associated with switching treatments and then using this estimated effect to derive counterfactual survival times 
for switchers ± those that would have been observed if switching had not occurred. 
TSEsimp ± assumptions  
The simple TSE approach, TSEsimp, relies on three assumptions (see Box 1):[12] (i) Switching must only occur 
at or after a disease-related secondary baseline time-point; (ii) from the point of the secondary baseline, 
switching is independent of potential outcomes, conditional on variables measured at or before the secondary 
baseline time-point, and; (iii) if switching happens after the secondary baseline, there must be no time-
dependent confounding between the secondary baseline time-point and the time of switch ± that is, post-
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secondary baseline values of prognostic variables must not influence the probability of switching. Essentially, 
there must be no confounding that is not accounted for in the TSEsimp model used to estimate the effect of 
switching. This is referred to as no unmeasured confounding, where a confounder is a variable that influences 
the treatment decision and is prognostic for the outcome of interest (i.e. survival).  
TSEsimp ± modelling approach 
TSEsimp involves a model for the effect of treatment switching on survival time and an outcomes model, which 
may be used to estimate the effect of the intervention on survival using the estimated survival times from the 
adjustment procedure. These models must be correctly specified in order for TSEsimp to provide appropriate 
estimates of the effect of being randomised to experimental treatment adjusted for treatment switching  (see Box 
1). 
A standard parametric accelerated failure time model (e.g. Weibull or Generalised Gamma) is used to estimate 
the effect of switching on survival time.[12] Post-secondary-baseline survival times in control group switchers 
are compared to those in control group non-switchers. The model includes covariates for prognostic 
characteristics measured at the secondary baseline time-point or before in an attempt to account for potential 
prognostic differences between switchers and non-switchers, and a switching variable ZKLFKHTXDOVµ¶DIWHUWKH
time of switch. The model provides an estimate of the treatment effect associated with switching in the form of a 
time-ratio, UHSUHVHQWLQJDPXOWLSOLFDWLYHIDFWRUE\ZKLFKDQLQGLYLGXDO¶VH[SHFWHGVXUYLYDOWLPHLVLQFUHDVHGRr 
decreased) by being on the treatment switched to, referred to as݁ିట.  
The inverse of the treatment effect, i.e. ݁ట, is then used to estimate counterfactual survival times ( ௜ܷ) for 
switchers. This implies using the causal interpretation of the model used to estimate the effect of treatment 
switching on survival times. The model assumes that treatment has a multiplicative effect on survival time and 
splits the observed event time, ௜ܶ , for each patient into time spent on the control treatment, ஼ܶ௜ , and time spent 
on the experimental treatment, ாܶ௜ . For control group switchers, ஼ܶ௜  is equal to the time from randomisation until 
switching occurs, and ாܶ௜  is equal to the time from switch until death or censoring. For non-switchers in the 
control group, ாܶ௜ ൌ  ?Ǥ The structural model for counterfactual survival times is therefore specified as follows: 
௜ܷ ൌ ஼ܶ௜ ൅ ݁ట ாܶ௜      (1) 
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Using (1), survival times are estimated for switching patients under a counterfactual scenario where they did not 
switch. For each switcher, values for ஼ܶ  and ாܶ  are plugged into (1), along with the estimate of ݁ట taken from 
the parametric accelerated failure time model used to estimate the effect of switching on survival time. Thereby, 
counterfactual survival times are estimated for switchers. In the absence of censoring, the adjustment for 
treatment switching is complete. However, if censoring is present, DQDGGLWLRQDOVWHSFDOOHG³re-censoring´ is 
required.[23-25] For switchers who are not observed to die, the model for counterfactual survival times results 
in a shrunken censoring time (assuming the treatment is beneficial). If switching is related to prognostic factors, 
shrinking censoring times in switchers (and not in non-switchers) will result in informative censoring because 
censoring times will be related to prognosis. Re-censoring breaks the dependence between the counterfactual 
censoring time and treatment received.[23-25] The counterfactual survival time associated with a given value of ߰ (that is, ௜ܷሺ߰ሻ) is re-censored for all patients in the treatment group in which switching occurs at the 
minimum of the administrative censoring time ܥ௜  and ݁టܥ௜, representing the earliest possible censoring time 
over all possible treatment trajectories, ܦ௜כሺ߰ሻ. ௜ܷሺ߰ሻ is then replaced by ܦ௜כሺ߰ሻ if ܦ௜כሺ߰ሻ ൏  ௜ܷሺ߰ሻ. Re-
censoring results in a loss of longer term information, which can be problematic if the aim is to estimate long-
term treatment effects ± this is discussed elsewhere.[26] 
After estimating untreated survival times for switchers and undertaking re-censoring if required, a new dataset is 
derived consisting of a mixture of observed (for non-switchers) and adjusted (for switchers) survival times. This 
dataset may be used to compare experimental and control group survival times using any outcomes model, to 
estimate the effect of experimental treatment adjusted for treatment switching. For instance, a Cox proportional 
hazards model might be used to estimate a hazard ratio.[27] Confidence intervals produced by the outcomes 
model will be inappropriate because they do not take into account that survival times have been adjusted in 
switchers ± bootstrapping the entire adjustment process is recommended to appropriately characterise 
uncertainty.[1,12] 
TSEsimp ± a variation 
TSEsimp relies upon simple regression and does not attempt to adjust for time-dependent confounders. A 
variation of this approach is to include time-dependent variables in the simple regression model used to estimate 
the effect of switching. For reasons previously described and illustrated in Figure 4, this approach is prone to 
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bias. However, in order to highlight the inadequacies of using simple regression adjustment to control for time-
dependent confounding we include this approach in this study, denoted TSEsimpTDC.  
Two-stage Estimation ± g-estimation approach 
TSEgest ± concept  
Through its use of g-estimation and a structural nested model (SNM), TSEgest allows the assumptions of 
TSEsimp to be relaxed because it is capable of dealing with time-dependent confounding, provided its own 
assumptions hold.[20,28,29] Importantly, the method does not even require that a secondary baseline exists ± for 
instance, it is applicable if switching happens before or after disease progression. However, in this study we are 
interested in a situation where switching only happens at or beyond disease progression. In this context, where 
the risk of switching is zero before progression, it is reasonable to apply TSEgest using disease progression as a 
secondary baseline. We describe TSEgest in this setting, in which it involves the same concept as TSEsimp ± a 
treatment effect associated with treatment switching is estimated which is then used in a counterfactual survival 
model to estimate untreated survival times for switchers. 
TSEgest ± assumptions  
TSEgest involves modelling switching and relies on one key assumption (see Box 1):[29] switching is 
independent of potential outcomes, conditional on measured variables ± that is, there is no unmeasured 
confounding. It is not a problem if post-secondary-baseline values of prognostic variables influence the 
probability of switch, provided those variables are measured and included in the analysis.  
TSEgest ± modelling approach 
TSEgest involves a model for switching, a counterfactual survival model, and an outcomes model. Each of these 
models must be correctly specified in order for TSEgest to provide appropriate estimates of the effect of being 
randomised to experimental treatment adjusted for treatment switching (see Box 1). 
The switching model is used in combination with g-estimation to estimate ݁ିట, that is, the treatment effect 
associated with switching in the form of a time-ratio also used by TSEsimp. The no unmeasured confounding 
assumption means that switching at each measurement occasion is independent of counterfactual survival times 
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௜ܷ, conditional on measured variables.[20] The switching model therefore relates treatment at each measurement 
observation to counterfactual survival time given a specific value for ȥ controlling for all confounders and the 
g-estimation procedure searches for the value of ȥthat results in independence between switch status and ௜ܷ. 
For instance, from Sterne and Tilling (2002) [20]:  
݈݋݃݅ݐ൫݌ሺܧ௜௞ሻ൯ ൌ ߙ ௜ܷǡట ൅  ? ߚ௝ݔ௜௝௞௝  (2) 
where  ܧ௜௞ is observed switch status for individual i at observation k, ௜ܷǡట is the counterfactual survival time for 
individual i given a specific value for ȥ, and ݔ௜௝௞ are all confounders for individual i at observation k. If 
TSEgest is applied from a secondary baseline, ௜ܷǡట refers to post-secondary-baseline counterfactual survival; the 
structure of the counterfactual survival model used to estimate this is the same as in (1), but ஼ܶ௜  refers to the 
time spent after the secondary baseline on control treatment, and ாܶ௜  refers to the time spent after the secondary 
baseline on the experimental treatment. The switching model and the post-secondary-baseline counterfactual 
survival model are used simultaneously to provide the g-estimate of ݁ିట. 
The g-estimation procedure involves fitting a series of models defined by (2) for a range of values of ȥ 
searching for the value of ȥ WKH³J-HVWLPDWH´IRUZKLFKswitch status at each measurement occasion is 
independent of ௜ܷ. This assessment is based on a test statistic for Į in (2) that is zero (that is, the P-value is 1), 
meaning that there is no association between current treatment and ௜ܷǡట. Typically a Wald statistic is used.[20] 
The upper and lower limits of the 95 percent confidence interval for ȥ are the two values for which the two-
sided P-values for the test statistic of Į are 0.05.  
Once ȥhas been identified it is used in (1) to estimate counterfactual survival times for patients who switched 
treatments, as in TSEsimp, resulting in a new dataset consisting of a mixture of observed and unobserved 
survival times. When censoring is present, re-censoring is required. Then, an outcomes model is used to 
estimate the effect of experimental treatment adjusted for treatment switching. Again, bootstrapping of the entire 
adjustment process is required to appropriately characterise uncertainty.    
Inverse Probability of Censoring Weights  
IPCW ± concept  
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IPCW can be used to adjust for treatment switching and can cope with time-dependent confounders. IPCW 
involves censoring patients at the time of switch but then weighting remaining observations using information 
on baseline and time-dependent patient characteristics to avoid the selection bias associated with the 
censoring.[1,18] 
IPCW ± assumptions  
IPCW involves modelling the switching process and is reliant on one key assumption (see Box 1): that there is 
no unmeasured confounding.[1,18,29] The definition of a confounder is the same as for the TSE methods ± that 
is, a variable that influences the probability of switching and is prognostic for survival. Therefore, data must be 
available on all such variables.[30,31]  
IPCW ± modelling approach  
IPCW involves a switching model and an outcomes model. The switching model is used to estimate weights, 
which are then used in the outcomes model to estimate a treatment effect adjusted for treatment switching. 
These models must both be correctly specified in order for IPCW to provide unbiased estimates of the effect of 
being randomised to experimental treatment, adjusted for treatment switching (see Box 1). The method is not 
applicable if there are any covariate patterns which ensure (i.e. the probability equals 1) that treatment switching 
will occur.[18,31,32] 
IPCW is often applied working in discrete time, dividing follow-up into small intervals and using pooled 
logistic regression.[18] First, a model for switching is fitted, controlling for all baseline and time-varying 
confounders. This model is used to estimate the probability of switching for each individual in each interval. An 
LQGLYLGXDO¶VSUREDELOLWLHVRIUHPDLQLQJXQVZLWFKHGXSWRLQWHUYDOt are then multiplied together, with the weight 
representing the inverse probability of remaining unswitched up to interval t. These weights can be highly 
variable, decreasing statistical efficiency,[33] and therefore stabilised weights are often used instead[18]: 
෡ܹ ሺݐሻ ൌ  ? ௉௥෢ ሾ஼ሺ௞ሻୀ଴ȁ஼ҧሺ௞ିଵሻୀ଴ǡ஺ҧሺ௞ିଵሻǡ௏ǡ்வ௞ሿ௉௥෢ ሾ஼ሺ௞ሻୀ଴ȁ஼ҧሺ௞ିଵሻୀ଴ǡ஺ҧሺ௞ିଵሻǡ௅തሺ௞ሻǡ்வ௞ሿ௧௞ୀ଴     (3) 
where ܥሺ݇ሻ is an indicator function demonstrating whether or not switching had occurred at the end of interval ݇, and ܥҧሺ݇ െ  ?ሻ denotes switching history to the end of the previous interval. ܣҧሺ݇ െ  ?ሻ GHQRWHVDQLQGLYLGXDO¶V
treatment history up to the end of the previous interval, and ܸ LVDQDUUD\RIDQLQGLYLGXDO¶VEDVHOLQHFRYDULDWHV
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ܮതሺ݇ሻ GHQRWHVWKHKLVWRU\RIDQLQGLYLGXDO¶VWLPH-dependent covariates measured at or prior to the beginning of 
interval ݇ and includes ܸ. Only baseline and time-dependent confounding variables need to be included in ܸ and ܮതሺ݇ሻ.  
The denominator of (3) represents the probability of an individual remaining unswitched at the end of interval k 
given that he or she had not switched at the end of the previous interval ሺ݇ െ  ?ሻ, conditional on baseline 
confounders, time-dependent confounders and treatment history ± as estimated by the switching model. The 
numerator of (3) represents that same probability, but is conditional only on baseline confounders and treatment 
history. For unstabilised weights, this numerator would simply equal 1. The idea behind stabilised weights is 
that the numerator is made as similar as possible to the denominator without re-introducing confounding ± time-
dependent confounders must not be included in the numerator.[34] 
Inverse probability weights can be incorporated within any outcomes model to adjust for treatment switching. 
Any baseline confounders ܸ included in the numerator of the weighting model should be included in the 
weighted outcomes model.[17] Ordinary standard errors are not valid in a weighted analysis and these must 
instead be computed in a robust way, using the sandwich variance. 
Rank preserving structural failure time models 
RPSFTM ± concept  
The RPSFTM involves a similar concept to TSEsimp and TSEgest ± a treatment effect associated with 
switching is estimated and this is used to derive what survival times would have been in the absence of 
switching. Unlike the TSE methods, the RPSFTM does not differentiate between the treatment effect in the 
experimental group and the treatment effect in switchers ± the treatment effect ߰ is assumed to be the same 
irrespective of when treatment is received. This may be regarded as a disadvantage, particularly in the context of 
post-progression switching in an oncology trial, as progressive disease may alter capacity to benefit. However, 
by making this assumption ± in combination with g-estimation designed specifically for an RCT context ± the 
RPSFTM avoids the no unmeasured confounding assumption.[16,35]  
RPSFTM ± assumptions   
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The RPSFTM makes two crucial assumptions (see Box 1): (i) Potential outcomes are independent of 
randomised group, and; (ii) there is a common treatment effect (that is, the time ratio ȥ is equal for all treated 
patients).[16,35]  
RPSFTM ± modelling approach  
The RPSFTM involves a counterfactual survival model to estimate untreated survival times for all randomised 
patients, and an outcomes model used to estimate the effect of experimental treatment adjusted for treatment 
switching. These models must be correctly specified in order for RPSFTM to provide unbiased estimates of the 
effect of being randomised to experimental treatment adjusted for treatment switching (see Box 1). 
For the simple one-parameter RPSFTM the counterfactual survival model splits the observed event time ( ௜ܶ) for 
each patient into the time spent on the control treatment ( ஼ܶ௜) and the time spent on the experimental treatment 
( ாܶ௜  ). ௜ܶ  is related to the counterfactual event time ( ௜ܷ) with the same model as presented in (1). The value of ȥ 
is estimated using g-estimation.[36] For a range of values of ȥ, the counterfactual survival model (1) is used to 
estimate ௜ܷ, and the true value is that which results in ௜ܷ being independent of randomised groups, based upon a 
g-test.[37] The g-test (e.g. log-rank, Cox) tests the hypothesis that the counterfactual (untreated) survival curves 
are identical in the two treatment groups, with the point estimate of ȥ being that for which the test (z) statistic 
equals zero.  
The g-estimation process results in counterfactual survival times estimated for the g-estimate of ȥ. A new 
dataset is derived consisting of observed survival times for experimental group patients and control group non-
switchers, and counterfactual survival times for switchers. When censoring is present, re-censoring (for all 
patients in treatment groups affected by switching) is incorporated within the g-estimation process. Then, an 
outcomes model is used to estimate the effect of experimental treatment adjusted for treatment switching. The P-
value produced by the outcomes model is likely to be too small and confidence intervals too narrow because 
they do not account for the fact that the data have been adjusted. It is recommended that the P-value from an 
equivalent ITT analysis should be used and confidence intervals calculated accordingly,[16,38] or, as for the 
TSE methods, the entire adjustment procedure could be bootstrapped.  
Simulation study  
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Detailed information on our simulation study, including code used to simulate the data, is provided in the 
appendices. Here we provide a brief summary of our aims, data generating mechanism, estimand, methods 
included and performance measures. The simulation study was conducted using Stata software, version 
14.2.[39] 
Aims 
Our objective was to assess the performance of TSEgest compared to TSEsimp, IPCW and RPSFTM in 
adjusting for treatment switching in simple scenarios, where time-dependent confounding is not an issue, and in 
more complex scenarios affected by time-dependent confounding. We focus on the problem typically seen in 
HTA whereby a subset of patients randomised to the control group of an RCT switch onto the experimental 
treatment after disease progression. Our aim is to estimate what survival would have been in the control group if 
switching had not occurred.  
Data generating mechanism 
In common with previous simulation studies,[13,26] we simulated datasets with a sample size of 500 and 2:1 
randomisation in favour of the experimental group, and with treatment switching permitted from the control 
group onto the experimental treatment. A step-by-step description of our data generating mechanism is provided 
in Appendix A. 
Our primary interest was in the performance of the adjustment methods in scenarios when time-dependent 
confounding was present, and when time-dependent confounding was not present. To this end, we simulated a 
VHWRIµVLPSOH¶VFHQDULRVZKLFKGLGQRWLQFOXGHWLPH-dependent confounding) aQGDVHWRIµFRPSOH[¶VFHQDULRV
(where time-GHSHQGHQWFRQIRXQGLQJZDVSUHVHQW,QWKHµVLPSOH¶VFHQDULRVFRQWUROJURXSSDWLHQWVFRXOGRQO\
switch onto the experimental treatment immediately upon disease progression ± no switching before or after this 
time point was allowed. Hence, there could be no time-dependent confounding between the time of progression 
DQGWKHWLPHRIVZLWFK,QWKHµFRPSOH[¶VFHQDULRVFRQWUROJURXSSDWLHQWVFRXOGVZLWFKRQWRWKHH[SHULPHQWDO
treatment either immediately upon disease progression or beyond this time point. A post-progression 
FRQIRXQGLQJYDULDEOHUHIHUUHGWRDVµPHWDVWDWLFGLVHDVH¶ZDVVLPXODWHGWRHQVXUHWKDWWKHVHVFHQDULRVZHUH
affected by time-dependent confounding. In addition, there was an interaction between the effect of switching 
and the metastatic disease variable. In patients who had not yet developed metastatic disease, switching 
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treatments reduced the probability of subsequently developing metastatic disease. In patients who had developed 
metastatic disease, switching treatments extended survival but did not alter the fact that metastatic disease had 
been developed. Hence treatment effect heterogeneity was present. 
In addition to the existence of time-dependent confounding, we considered that the size of the treatment effect, 
the switching proportion, and whether or not censoring was present could affect the performance of the 
adjustment methods. Hence, scenarios were run varying the following characteristics:  
x Treatment effect: low (average HR under the assumption of proportional hazards (which is an incorrect 
assumption in complex scenarios) approximately 0.82); high (average HR approximately 0.61)  
x Switch proportion: moderate (approximately 50% of control group patients who experienced disease 
progression); high (approximately 75% of control group patients who experienced disease progression)  
x Censoring: none; present (administrative censoring proportion approximately 20-35%) 
x Time-dependent confounding: none (in simple scenarios); present (in complex scenarios) 
Using a 2x2x2x2 factorial design resulted in a total of 16 scenarios. The scenarios were numbered 1-16 with all 
levels of one factor nested inside one level of the next factor, following the order listed above. Details on 
scenario values and settings are presented in Appendices B and C. Scenarios 1-8 were the simple scenarios, in 
which the metastatic disease time-dependent confounder was not included. Scenarios 9-16 were the complex 
scenarios, which included the time-dependent confounder. Scenarios 15 and 16 were re-run simulating a sample 
size of 10,000 instead of 500, because we anticipated that IPCW and TSEgest may be prone to high error levels 
with relatively small sample sizes. Repeating these scenarios with a much larger sample size allowed us to 
assess this. Therefore, in total 18 scenarios were run. One thousand simulations were run for each scenario.  
Estimand 
Our estimand was restricted mean survival time (RMST) in the control group, consistent with our aim of 
investigating the performance of adjustment methods in estimating survival times for the control group that 
would have been observed in the absence of treatment switching. 
In the simple scenarios, it was possible to integrate the simulated survival function to calculate true RMST (see 
equations (A1)-(A3) in Appendix A). In the complex scenarios the survival function was not analytically 
WUDFWDEOHVRWRHVWLPDWHRXU³WUXH´YDOXHIRUHDFKVFHQDULRZHVLPXODWHGGDWDIRUSDWLHQWVZLWKRXW
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incorporating treatment switching, and estimated control group RMST by calculating the area under the Kaplan 
Meier survival function. This value is the product of a simulation so is prone to error, but this is minimal given 
the large number of patients simulated. For instance, in Scenario 1, the standard error of the control group 
RMST estimate of 424.37 days was 0.48. In scenarios that did not include censoring RMST was effectively 
unrestricted because death was observed in all simulated patients. In scenarios that included censoring RMST 
was estimated up to 546 days (the maximum administrative censoring time in the simulated datasets).  
Adjustment methods compared  
TSEsimp, TSEgest, RPSFTM and IPCW were included and their application is described in detail in Appendix 
D. TSEsimpTDC was only included only in Scenarios 9-18 because in Scenarios 1-8, where switching could 
only occur immediately at the point of disease progression, TSEsimpTDC simplifies to TSEsimp. As described 
previously, TSEsimp (and TSEsimpTDC), TSEgest and RPSFTM involve estimating a treatment effect 
associated with switching and then using this to derive counterfactual survival times, whereas IPCW results in 
weighted survival times. We used the Stata command stpm2 [40] to fit flexible parametric models to the 
counterfactual datasets provided by TSEsimp, TSEsimpTDC, TSEgest and RPSFTM, and to the weighted 
survival times provided by IPCW, to obtain the survivor function extrapolated (if necessary) to 546 days, 
HQVXULQJWKDWRXU5067FRPSDULVRQVZHUHFRPSDULQJ³OLNHZLWKOLNH´1RQ-parametric methods to estimate 
RMST up to the final follow-up time-point could not be used because, in scenarios that included censoring, 
when re-censoring is applied (for the TSE and RPSFTM methods) the re-censored final follow-up time-point 
may differ from 546 days and may differ for each adjustment method. Using flexible parametric models is 
consistent with UK HTA recommendations for undertaking survival modelling in the presence of complex 
hazard functions.[41,42]  
To provide context on the performance of the varLRXVDGMXVWPHQWPHWKRGVZHLQFOXGHGDµ1R6ZLWFKLQJ¶
analysis, representing the results of a standard ITT analysis (that is, an unadjusted estimate of control group 
RMST) undertaken on the simulated dataset before switching was applied. This represents thH³WUXWK´IRUHDFK
simulation and does not represent a feasible estimator, but provides a useful upper bound for adjustment method 
SHUIRUPDQFHZKLFKPD\EHFRQVLGHUHGDµJROGVWDQGDUG¶:HDOVRLQFOXGHGDVWDQGDUG,77DQDO\VLVDIWHU
switching was applied. Though this has a different estimand to the adjustment methods (because it does not 
adjust for switching), it is standard practice to present an ITT analysis even in the presence of treatment 
switching.  
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Performance measures  
The performance of methods was evaluated according to the percentage bias in their estimate of control group 
RMST at 546 days. Percentage bias was estimated by taking the difference between the mean estimated RMST 
and the true RMST and expressing this as a percentage of true RMST.[43] Root mean squared error (RMSE) 
and empirical standard errors (SE) of the RMST estimates were also calculated for each method and expressed 
as percentages of the true RMST. Convergence was measured, defined as the proportion of times that each 
method resulted in an estimate of control group RMST. Percentage bias, RMSE and empirical SE were 
calculated based upon simulations in which convergence occurred. Monte Carlo (MC) standard errors were 
calculated for each performance measure, for each method.[44] For methods that incorporated IPCW, we 
recorded the mean, standard deviation, minimum, maximum and coefficient of variation of the weights 
measured across control group patients in each simulated data set, in order to explore the relationship between 
these and the performance of the method. 
RESULTS 
First, we present results from the simple scenarios, focusing on results from one scenario to illustrate the key 
findings. We then repeat this for the complex scenarios. A summary table describing the data generated under 
each scenario is presented in Appendix E.  
Results from simple scenarios  
The upper half of Table 1 presents detailed results from Scenario 2, which included no time-dependent 
confounder, a large treatment effect, a moderate switch proportion and zero censoring. The ITT analysis over-
estimated control group RMST, equivalent to a percentage bias of 12.4%. TSEsimp, TSEgest, RPSFTM and 
IPCW all predicted control group RMST with very little percentage bias, ranging from 0.0% for RPSFTM to 
1.0% for TSEgest. TSEsimp resulted in empirical standard errors and RMSE that were approximately 10-13% 
lower than those from by TSEgest, RPSFTM and IPCW.  
Results were similar across all simple scenarios (Scenarios 1-8) for all methods except IPCW and ITT, as 
illustrated by Figures 5-7, which present nested loop plots for percentage bias, empirical SE and RMSE across 
all scenarios.[45] Across Scenarios 1-8, TSEsimp and IPCW resulted in least percentage bias in 3 scenarios 
apiece and RPSFTM resulted in least percentage bias in 2 scenarios. All methods always had percentage bias of 
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less than 1.4%, except IPCW which resulted in percentage bias of approximately 3% in Scenarios 3 and 4, in 
which the switching proportion was high. TSEsimp consistently generated lower empirical standard errors than 
the other adjustment methods in the simple scenarios, with these ranging between 0-20% lower than the 
empirical standard errors associated with TSEgest, 11-49% lower than those associated with RPSFTM, and 9-
63% lower than those associated with IPCW. This contributed to TSEsimp always resulting in the lowest RMSE 
of all the adjustment methods in the simple scenarios.  
Results from complex scenarios  
Table 1 also presents detailed results from Scenario 10, which was similar to Scenario 2 with respect to 
treatment effect, switch proportion and censoring, but included time-dependent confounding. The ITT analysis 
again over-estimated control group RMST, equivalent to a percentage bias of 7.3%. TSEsimp resulted in high 
percentage bias in Scenario 10 ± over-estimating control group RMST to almost the same extent as the ITT 
analysis (percentage bias 5.6%). In contrast, TSEgest, RPSFTM and IPCW generated very low percentage bias 
(-0.6% for TSEgest, -0.1% for RPSFTM and 0.6% for IPCW). TSEsimpTDC resulted in percentage bias (6.9%) 
that was similar in size to that of TSEsimp. TSEgest resulted in an empirical standard error that was 
approximately 10% lower than that of TSEsimp, RPSFTM and IPCW, and also generated the lowest RMSE. 
TSEsimp produced substantially higher RMSE due to its increased bias.  
Results for RPSFTM and TSEgest were relatively stable in all the complex scenarios, as illustrated in Figures 5-
7. These methods consistently resulted in low bias, although TSEgest was prone to slightly increased bias (up to 
approximately 2%) in scenarios with a high switching proportion. TSEsimp (and TSEsimpTDC) consistently 
resulted in much higher levels of bias than TSEgest and RPSFTM, with increased switching proportions and 
treatment effect sizes associated with higher bias. IPCW resulted in low bias in Scenarios 9, 10, 13 and 14, when 
the switching proportion was moderate (approximately 50%), but produced much higher bias in Scenarios 11, 
12, 15 and 16, when the switching proportion was high (approximately 75%).  
The switching proportions in Scenarios 11-12 and 15-16 were not different to those simulated in simple 
Scenarios 3-4 and 7-8, in which IPCW resulted in low bias. However, the incorporation of the time-dependent 
confounding variable meant that additional covariates were used in the TSEgest and IPCW switching models, 
which, combined with a low sample size and high switching proportion resulted in slightly increased bias for 
TSEgest and substantially increased bias for IPCW. Re-running Scenarios 15 and 16 with a much larger sample 
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size (in Scenarios 17 and 18) had minimal impact on TSEgest, but resulted in substantially reduced bias for 
IPCW. In Scenarios 17 and 18 IPCW produced weights that were much lower as a proportion of the size of the 
group being subjected to weighting, compared to Scenarios 15 and 16 (and Scenarios 11 and 12). Within 
Scenarios 1-16, the range of weights was widest in Scenarios 11, 12, 15 and 16, with average minimum and 
maximum weights of approximately 0.02 and 18 in these scenarios, in a control group made up of 
approximately 170 patients. The coefficient of variation of the weights was also highest in these scenarios 
(approximately 0.77) but this was not substantially different to the coefficient of variation in scenarios in which 
the IPCW worked well (e.g. Scenarios 3, 4, 7 and 8). In Scenarios 17 and 18 the range of weights and the 
coefficient of variation increased (average minimum and maximum weight 0.02 and 71, coefficient of variation 
0.98-0.99), but the maximum weight was much lower as a proportion of the size of the group being subjected to 
weighting, as approximately 3,400 patients were randomised to the control group in these scenarios. This 
indicates that it is the size of the maximum weight in relation to the size of the group being subjected to 
weighting that is a key determinant of the bias associated with IPCW. In Scenarios 1-8 the maximum weight as 
a proportion of the control group sample size varied between 3 and 6% and in Scenarios 9-10, 13-14 and 17-18 
was approximately 2%. However, in Scenarios 11, 12, 15 and 16 this proportion increased to 10-11%.       
Across Scenarios 9-18, RPSFTM generated least percentage bias in 7 scenarios and IPCW in 3 scenarios. 
Neither TSEsimp or TSEgest resulted in least percentage bias in any of these scenarios, but percentage bias was 
considerably lower for TSEgest than TSEsimp in all of these scenarios, and levels of bias associated with 
TSEgest were not substantially different from those associated with RPSFTM. IPCW resulted in much higher 
percentage bias than TSEgest and RPSFTM in Scenarios 11, 12, 15 and 16. TSEsimp produced lower empirical 
standard errors than the other adjustment methods in scenarios which incorporated censoring (Scenarios 13-18), 
but TSEgest produced the lowest empirical standard errors in scenarios without censoring (Scenarios 9-12). 
Across Scenarios 9-18, TSEgest resulted in lowest RMSE in 6 scenarios, RPSFTM in 3 scenarios and IPCW in 
1 scenario.  
DISCUSSION  
In scenarios without time-dependent confounding, TSEsimp resulted in estimates of control group RMST that 
had similar or lower bias than the complex adjustment methods, and had less variability. However, in scenarios 
with time-dependent confounding TSEsimp resulted in estimates that had substantially higher bias than TSEgest 
and RPSFTM. IPCW also resulted in substantially lower bias than TSEsimp in scenarios with time-dependent 
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confounding, provided the inverse probability weights were not too high. Overall, if time-dependent 
confounding is unlikely, TSEsimp remains an appropriate adjustment method. But if time-dependent 
confounding is a possibility ± for instance, due to long time periods between the secondary baseline and the 
switching time, or due to measured prognostic events that occurred between these two time-points ± TSEgest, 
RPSFTM and IPCW should be considered instead. 
In scenarios with time-dependent confounding, TSEsimp over-estimated control group RMST to almost the 
same extent as the ITT analysis ± sometimes actually resulting in a higher estimate of control group RMST than 
the ITT analysis. This is because patients who experienced the metastatic event (which drastically reduced 
survival times) were more likely to switch (as explained in Appendix A). Failing to account for this constitutes 
confounding by indication and results in switching appearing to have only a very minor beneficial effect, or in 
fact in switching appearing harmful. The opposite would be the case if switching was more likely in patients 
who had not experienced the metastatic event. Either way, in the presence of such time-dependent confounding, 
TSEsimp becomes prone to high levels of bias. Controlling for a time-dependent confounder using simple 
regression is inadequate and inappropriate, because we control for a variable through which treatment has an 
effect on the outcome of interest ± as demonstrated by the biased results associated with the TSEsimpTDC 
analyses. 
We demonstrated that correctly specified TSEgest and IPCW models were able to deal with the time-dependent 
confounding caused by the metastatic disease variable. Interestingly, TSEgest was more robust to high 
switching proportions in small sample sizes than IPCW. This is in line with theory, because when positivity 
begins to break down in a particular subgroup (due to very small numbers of patients who do not switch) IPCW 
is more prone to error because it weights remaining observations in that subgroup ± often resulting in very high 
weights ± whereas TSEgest remains able to estimate the treatment effect using data from other subgroups. In 
practice, violations of the positivity assumption are possible when certain prognostic characteristics are highly 
predictive for switching. Our IPCW results reflect previous findings, with the added reassurance that the method 
can perform well even in the presence of serious time-dependent confounding ± provided models are accurately 
specified and weights are not too high. Previous studies have demonstrated that IPCW performs well when 
weights are not extreme,[12,13,26,46] and have discussed the definition of weights that are too high or have too 
great a range or coefficient of variation.[12,13,26] In this study we found that the coefficient of variation did not 
seem to be the most important determinant of bias associated with IPCW ± instead it appeared that the size of 
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the weights in relation to the sample size of the group subject to weighting was the critical factor. We are unable 
to draw firm conclusions, but we found that when the maximum weight as a proportion of the group being 
weighted was less than 6% the IPCW method resulted in low bias, but when this proportion increased to 10-
11% bias increased substantially.       
Our study also provides further information on the performance of the RPSFTM, which performed well across 
all scenarios, often resulting in the lowest percentage bias in scenarios that involved time-dependent 
confounding ± though TSEgest more often generated the lowest RMSE in these scenarios. It is important to note 
± and is a limitation of our study ± that we only simulated scenarios that involved an approximately common 
treatment effect between switchers and patients randomised to the experimental group. Previous studies have 
consistently shown that RPSFTM performs well in these circumstances,[12,13,14,26] although these have not 
involved important time-dependent confounding variables similar to the metastatic disease variable simulated in 
this study. Hence our results provide increased confidence that the RPSFTM method is reliable even in the 
presence of serious time-dependent confounding. However, as previously demonstrated,[12,13,26] performance 
of the RPSFTM worsens when the common treatment effect assumption does not hold and sensitivity analysis 
should always be undertaken around this.[6] Linked to this, the RPSFTM method is only likely to be appropriate 
in situations where treatment switching is between randomised treatments. In contrast, TSE and IPCW methods 
could be used irrespective of what treatment patients switched on to. 
It is useful to note that using g-estimation substantially increases the flexibility of the TSE adjustment method ± 
the approach may be thought of as generalised TSE. In fact, because the approach can account for time-
dependent confounding, it is not necessary to use a secondary baseline. If treatment switching was only 
permitted after disease progression, the SNM could be fit from baseline with disease progression included as a 
time-dependent indicator variable. In such a case we would expect the model to provide the same results as if it 
was fitted only from the disease progression time-point, because switching only occurred after progression and 
thus the switching model would only use data from the point of disease progression onwards ± prior 
observations would be excluded due to perfectly predicting non-switching. However, whilst TSEsimp is not 
appropriate in circumstances where some (or all) switching occurs before disease progression, the SNM with g-
estimation method could be used ± representing an important advantage of this approach. An additional practical 
point worthy of note is that data must be in discrete time interval format for TSEgest to be applied. If variables 
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were measured in continuous time we would need to discretise time. However, narrow time intervals could be 
used and we expect that TSEgest could still work well.     
Our study has limitations. We used estimates of control group RMST to assess the performance of the 
adjustment methods. This may seem unexpected given our focus on comparing TSEsimp and TSEgest ± two 
methods that begin by estimating the treatment effect in switchers. However, we could not use this treatment 
effect as our estimand because this would not have allowed us to make broader conclusions around the 
performance of the TSE methods in relation to the other adjustment methods. RPSFTM and IPCW do not 
estimate a treatment effect specific to switchers, so this could not be used as a comparative measure. 
The fact that our study consists of simulations may also be considered to be a limitation. Though we 
investigated several realistic scenarios, these can never cover all situations that may occur in reality. Because we 
knew the underlying data generating process we were able to correctly specify switching models for TSEgest 
and IPCW. In the real world, careful thought must be given to how variables are linked, as model mis-
specification will likely result in bias. This illustrates the importance of paying close attention to model 
specification; it is not enough to simply identify a method that could work, we must consider how the method 
should actually be applied. In our study we simulated a metastatic disease variable and assumed that this 
variable had a lagged effect on treatment choices. We think this is realistic ± there is often a lag between 
ordering laboratory tests or scans, receiving the results and making treatment decisions. Therefore, using lagged 
values of variables in switching models is often likely to be sensible. Careful thought regarding causal pathways 
is necessary when specifying models that rely on no unmeasured confounding to account for time-dependent 
confounding, and clinical expert knowledge is likely to be crucial.    
It is a limitation that we did not consider coverage in this study. Previous simulation studies have reported 
coverage, but in a limited way.[12,13,14,26] To properly account for uncertainty around survival estimates 
provided by RPSFTM and TSE methods bootstrapping is required, but is not feasible in simulation studies that 
investigate many scenarios. Without bootstrapping, estimates of coverage are not useful, and so we decided not 
to include them in this study.  In practice, the entire RPSFTM, TSE and IPCW adjustment processes should be 
bootstrapped to obtain appropriate confidence intervals. In one previous study it was demonstrated that this 
results in adequate coverage levels, in scenarios where adjustment methods result in low bias.[47] We therefore 
chose to focus on bias in this study, and are confident that methods that produce low bias would provide 
adequate standard errors and coverage provided bootstrapping is used. 
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Finally, it is worthy of note that in our complex scenarios treatment effect heterogeneity was simulated. Patients 
who switched after developing metastatic disease received a singular treatment effect of increased survival time, 
whereas patients who switched before developing metastatic disease received an additional treatment effect 
through reduced subsequent risk of developing metastatic disease. In our application of TSEgest, we did not 
include an interaction term for the treatment effect and the metastatic disease variable ± doing so is not trivial in 
a g-estimation procedure. Hence the method estimated an average treatment effect across all switchers, rather 
than two separate effects dependent on metastatic disease status. This is a limitation, but we have shown that the 
method still produces little bias. However, this may explain why the method often produced some bias (1-2%) in 
the complex scenarios.  
We have demonstrated the performance of TSEgest, an alternative to the simple TSE method (TSEsimp) that 
has been used in health technology assessment to adjust for treatment switching.[48-50] TSEsimp is efficient 
and unbiased provided there is no time-dependent confounding between the time that switch becomes possible 
and the time that switch actually occurs. However, if there is a gap between these two time-points and 
prognostic events occur during this period TSEsimp results in serious bias, whereas TSEgest does not. RPSFTM 
and IPCW methods can also result in low levels of bias in the presence of time-dependent confounding, but 
TSEgest holds some advantages over these methods ± being less prone to bias than IPCW in scenarios with high 
switching proportions and breakdowns in positivity, and, unlike the RPSFTM, not being reliant on the common 
treatment effect assumption. TSEgest represents a useful addition to the collection of methods that may be used 
to adjust for treatment switching in trials in order to address policy-relevant treatment reimbursement decision 
problems. 
.  
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FIGURES 
 
Figure 1. Illustrating treatment switching ± switching immediately upon disease progression 
Note: PFS: progression-free survival; PPS: post-progression survival; OS: overall survival; ITT: intention-to-
treat 
 
Figure 2. Illustrating treatment switching ± switching sometime after disease progression 
Note: PFS: progression-free survival; PPS: post-progression survival; OS: overall survival; ITT: intention-to-
treat 
 
Figure 3. Directed acyclic graph illustrating post-progression switching with no time-dependent confounding 
 
Figure 4. Directed acyclic graph illustrating post-progression switching with time-dependent confounding 
 
Figure 5. Percentage bias in estimation of control group restricted mean survival time across all scenarios 
Note: ITT: intention to treat; TSEsimp: two-stage estimation with simple Weibull model; TSEgest: two-stage 
estimation with g-estimation; RPSFTM: rank preserving structural failure time model; IPCW: inverse 
probability of censoring weights; TSEsimpTDC: two-stage estimation with simple Weibull model and time-
dependent covariates  
 
Figure 6. Empirical standard error in estimation of control group restricted mean survival time across all 
scenarios 
Note: ITT: intention to treat; TSEsimp: two-stage estimation with simple Weibull model; TSEgest: two-stage 
estimation with g-estimation; RPSFTM: rank preserving structural failure time model; IPCW: inverse 
probability of censoring weights; TSEsimpTDC: two-stage estimation with simple Weibull model and time-
dependent covariates; SE: standard error 
 
Figure 7. Root mean squared error in estimation of control group restricted mean survival time across all 
scenarios  
Note: ITT: intention to treat; TSEsimp: two-stage estimation with simple Weibull model; TSEgest: two-stage 
estimation with g-estimation; RPSFTM: rank preserving structural failure time model; IPCW: inverse 
probability of censoring weights; TSEsimpTDC: two-stage estimation with simple Weibull model and time-
dependent covariates; RMSE: root mean squared error 
 
 
ADDITIONAL MATERIAL 
Additional file 1: Appendices.docx 
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Box 1: Key assumptions of TSEsimp, TSEgest, IPCW and RPSFTM for estimating unbiased treatment effects 
in the presence of treatment switching 
TSEsimp 
 
Assumptions 
- Switching at or after a disease-related secondary baseline time-point 
- From the point of the secondary baseline, independence between switch status and potential outcomes, 
conditional on variables measured at or before the secondary baseline time-point (i.e. no unmeasured 
confounding) 
- If switching happens after the secondary baseline, no time-dependent confounding between secondary 
baseline and time of switch (i.e. post-secondary-baseline values of prognostic variables do not 
influence the probability of switch) 
Model specification 
- Correctly specified model for effect of switching on survival time 
- Correctly specified outcomes model 
TSEgest 
 
Assumptions 
- From the point of the secondary baseline, independence between switch status and potential outcomes, 
conditional on variables measured at or before, and after the secondary baseline time-point (i.e. no 
unmeasured confounding) 
Model specification 
- Correctly specified model for switching 
- Correctly specified model for counterfactual survival 
- Correctly specified outcomes model 
 
- Note: can be applied without a secondary baseline, with the resulting assumption: 
Independence between switch status and potential outcomes, conditional on variables measured at 
baseline and over time (i.e. no unmeasured confounding) 
IPCW 
 
Assumptions 
- Independence between switch status and potential outcomes, conditional on variables measured in 
unswitched observations (i.e. no unmeasured confounding) 
Model specification 
- Correctly specified model for switching  
- Correctly specified outcomes model 
- Not applicable if there are any covariates which ensure that switching will occur 
RPSFTM 
 
Assumptions 
- Independence between randomised groups and potential outcomes 
- Common treatment effect in all treated patients 
Model specification 
- Correctly specified model for counterfactual survival 
- Correctly specified outcomes model 
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Table 1:  Scenarios 2 and 10 ± performance measures for estimation of control arm RMST 
Scenario details Method 
Percent bias in 
RMST 
Empirical SE  
as % of true RMST  
RMSE  
as % of true RMST Convergence (%) 
Scenario number: 2 
True RMST: 
    Control:  424 
    Experimental:  600 
Mean switch: 50% 
True ave. HR: 0.61 
True ave. AF: 1.42 
Mean censored: 0% 
No switching -0.0 5.5 5.5 100 
ITT 12.4 6.3 13.9 100 
TSEsimp 0.4 7.4 7.4 100 
TSEgest 1.0 8.2 8.3 100 
RPSFTM 0.0 8.2 8.2 100 
IPCW 0.6 8.1 8.1 100 
min/max MC error 0.2/0.3 0.1/0.2 0.1/0.2 - 
Scenario number: 10 
True RMST: 
    Control:  338 
    Experimental:  465 
Mean switch: 51% 
True ave. HR: 0.65 
True ave. AF: 1.38 
Mean censored: 0% 
No switching -0.1 5.5 5.5 100 
ITT 7.3 6.0 9.5 100 
TSEsimp 5.6 7.0 9.0 100 
TSEsimpTDC 6.9 7.4 10.1 100 
TSEgest  -0.6 6.4 6.4 100 
RPSFTM -0.1 7.0 7.0 100 
IPCW 0.6 7.0 7.0 100 
min/max MC error 0.2/0.2 0.1/0.2 0.1/0.2 - 
Note: RMST: restricted mean survival time; HR: hazard ratio; AF: acceleration factor; SE: standard error; RMSE: root mean squared error; MC: 
Monte-Carlo; ITT: intention to treat; TSEsimp: two-stage estimation with simple Weibull model; TSEgest: two-stage estimation with g-estimation; 
RPSFTM: rank preserving structural failure time model; IPCW: inverse probability of censoring weights; TSEsimpTDC: two-stage estimation with 
simple Weibull model and time-dependent covariates 
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Figure 1. Illustrating treatment switching ± switching immediately upon disease progression 
Note: PFS: progression-free survival; PPS: post-progression survival; OS: overall survival; ITT: intention-to-
treat 
 
 
 
 
 
Figure 2. Illustrating treatment switching ± switching sometime after disease progression 
Note: PFS: progression-free survival; PPS: post-progression survival; OS: overall survival; ITT: intention-to-
treat 
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Figure 3. Directed acyclic graph illustrating post-progression switching with no time-dependent confounding 
 
 
 
 
Figure 4. Directed acyclic graph illustrating post-progression switching with time-dependent confounding 
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Figure 5. Percentage bias in estimation of control group restricted mean survival time across all scenarios 
Note: ITT: intention to treat; TSEsimp: two-stage estimation with simple Weibull model; TSEgest: two-stage estimation with g-estimation; RPSFTM: rank preserving 
structural failure time model; IPCW: inverse probability of censoring weights; TSEsimpTDC: two-stage estimation with simple Weibull model and time-dependent covariates  
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Figure 6. Empirical standard error in estimation of control group restricted mean survival time across all scenarios, expressed as a percentage of the true value. 
Note: ITT: intention to treat; TSEsimp: two-stage estimation with simple Weibull model; TSEgest: two-stage estimation with g-estimation; RPSFTM: rank preserving 
structural failure time model; IPCW: inverse probability of censoring weights; TSEsimpTDC: two-stage estimation with simple Weibull model and time-dependent 
covariates; SE: standard error 
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Figure 7. Root mean squared error in estimation of control group restricted mean survival time across all scenarios, expressed as a percentage of the true value.  
Note: ITT: intention to treat; TSEsimp: two-stage estimation with simple Weibull model; TSEgest: two-stage estimation with g-estimation; RPSFTM: rank preserving 
structural failure time model; IPCW: inverse probability of censoring weights; TSEsimpTDC: two-stage estimation with simple Weibull model and time-dependent 
covariates; RMSE: root mean squared error 
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